DK3325488T3 - Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer - Google Patents
Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer Download PDFInfo
- Publication number
- DK3325488T3 DK3325488T3 DK16828471.9T DK16828471T DK3325488T3 DK 3325488 T3 DK3325488 T3 DK 3325488T3 DK 16828471 T DK16828471 T DK 16828471T DK 3325488 T3 DK3325488 T3 DK 3325488T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- treatment
- chiral diaryl
- macrocycle
- diaryl macrocycle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195081P | 2015-07-21 | 2015-07-21 | |
| US201662302231P | 2016-03-02 | 2016-03-02 | |
| PCT/US2016/043132 WO2017015367A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3325488T3 true DK3325488T3 (da) | 2020-09-14 |
Family
ID=57834656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16828471.9T DK3325488T3 (da) | 2015-07-21 | 2016-07-20 | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
| DK20181616.2T DK3733187T3 (da) | 2015-07-21 | 2016-07-20 | Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20181616.2T DK3733187T3 (da) | 2015-07-21 | 2016-07-20 | Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20180325901A1 (da) |
| EP (3) | EP3733187B1 (da) |
| JP (1) | JP6817287B2 (da) |
| KR (1) | KR102772574B1 (da) |
| CN (1) | CN108026109B (da) |
| AU (1) | AU2016296878B2 (da) |
| BR (1) | BR112018001065A2 (da) |
| CA (1) | CA2992324A1 (da) |
| DK (2) | DK3325488T3 (da) |
| ES (2) | ES2993492T3 (da) |
| FI (1) | FI3733187T3 (da) |
| HK (1) | HK1254606A1 (da) |
| HR (1) | HRP20241615T1 (da) |
| IL (1) | IL256868B (da) |
| MX (1) | MX2018000718A (da) |
| PL (1) | PL3733187T3 (da) |
| PT (1) | PT3733187T (da) |
| RS (1) | RS66238B1 (da) |
| RU (2) | RU2728579C2 (da) |
| SI (1) | SI3733187T1 (da) |
| SM (1) | SMT202400496T1 (da) |
| WO (1) | WO2017015367A1 (da) |
| ZA (1) | ZA201800416B (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3572416T3 (pl) | 2014-01-24 | 2023-02-27 | Turning Point Therapeutics, Inc. | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| ES2979111T3 (es) * | 2015-07-06 | 2024-09-24 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo |
| ES2993492T3 (en) | 2015-07-21 | 2025-01-02 | Turning Point Therapeutics Inc | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN107267458B (zh) * | 2017-07-06 | 2019-10-29 | 中南大学湘雅二医院 | 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用 |
| SMT202400343T1 (it) | 2017-07-28 | 2024-11-15 | Turning Point Therapeutics Inc | Composti macrociclici e loro usi |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| EP3706749B1 (en) * | 2017-11-10 | 2024-03-13 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| WO2019184955A1 (en) * | 2018-03-28 | 2019-10-03 | Fochon Pharmaceuticals, Ltd. | Macrocyclic compounds as trk kinases inhibitors |
| JP7092405B2 (ja) * | 2018-04-16 | 2022-06-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジ（ヘテロ）アリール大環状化合物 |
| JP7128345B2 (ja) * | 2018-04-25 | 2022-08-30 | プライムジーン（ベイジン）カンパニー リミテッド | ジアリール大員環化合物、医薬組成物及びその用途 |
| WO2019210835A1 (zh) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| LT3870579T (lt) | 2018-10-22 | 2025-01-27 | Alumis Inc. | Tyk2 inhibitoriai ir jų naudojimas |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| EP3986413A4 (en) * | 2019-06-19 | 2023-06-14 | Turning Point Therapeutics, Inc. | POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR |
| KR20220134522A (ko) | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
| CN111689883B (zh) * | 2020-05-22 | 2022-02-11 | 上海应用技术大学 | 一种二芳基砜类化合物的合成方法 |
| WO2021244609A1 (zh) * | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0690843T3 (da) | 1993-03-25 | 2000-11-13 | Upjohn Co | Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet |
| ES2162843T3 (es) * | 1993-12-07 | 2002-01-16 | Lilly Co Eli | Inhibidores de la proteina quinasa c. |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CA2431187A1 (en) * | 2000-12-08 | 2002-06-13 | Ortho-Mcneil Pharmaceutical, Inc. | Macroheterocylic compounds useful as kinase inhibitors |
| EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| EP2334301B1 (en) | 2008-09-08 | 2018-02-14 | Merck Serono SA | Macrocyclics pyrimidines as aurora kinase inhibitors |
| US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
| SG10201900514RA (en) | 2008-10-22 | 2019-02-27 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| PE20110828A1 (es) | 2008-10-31 | 2011-11-22 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| JP5624148B2 (ja) | 2009-10-13 | 2014-11-12 | エランコ・アニマル・ヘルス・アイルランド・リミテッド | 大環状インテグラーゼ阻害剤 |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| AU2012299223A1 (en) | 2011-08-19 | 2014-02-27 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| WO2013045653A1 (en) | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
| ES2621220T3 (es) | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas |
| ES2676224T3 (es) | 2012-03-09 | 2018-07-17 | Lexicon Pharmaceuticals, Inc. | Compuestos a base de pirazolo[1,5-a]pirimidina, composiciones que los comprenden y métodos para usarlos |
| MX347917B (es) * | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| PL3572416T3 (pl) | 2014-01-24 | 2023-02-27 | Turning Point Therapeutics, Inc. | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| CA2989327A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| ES2979111T3 (es) * | 2015-07-06 | 2024-09-24 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo |
| ES2993492T3 (en) | 2015-07-21 | 2025-01-02 | Turning Point Therapeutics Inc | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| SMT202400343T1 (it) | 2017-07-28 | 2024-11-15 | Turning Point Therapeutics Inc | Composti macrociclici e loro usi |
-
2016
- 2016-07-20 ES ES20181616T patent/ES2993492T3/es active Active
- 2016-07-20 WO PCT/US2016/043132 patent/WO2017015367A1/en active Application Filing
- 2016-07-20 PL PL20181616.2T patent/PL3733187T3/pl unknown
- 2016-07-20 KR KR1020187002289A patent/KR102772574B1/ko active Active
- 2016-07-20 PT PT201816162T patent/PT3733187T/pt unknown
- 2016-07-20 CA CA2992324A patent/CA2992324A1/en active Pending
- 2016-07-20 EP EP20181616.2A patent/EP3733187B1/en active Active
- 2016-07-20 HR HRP20241615TT patent/HRP20241615T1/hr unknown
- 2016-07-20 SI SI201631859T patent/SI3733187T1/sl unknown
- 2016-07-20 EP EP24198628.0A patent/EP4480543A3/en active Pending
- 2016-07-20 FI FIEP20181616.2T patent/FI3733187T3/fi active
- 2016-07-20 ES ES16828471T patent/ES2818528T3/es active Active
- 2016-07-20 JP JP2018502668A patent/JP6817287B2/ja active Active
- 2016-07-20 US US15/745,915 patent/US20180325901A1/en not_active Abandoned
- 2016-07-20 DK DK16828471.9T patent/DK3325488T3/da active
- 2016-07-20 EP EP16828471.9A patent/EP3325488B1/en active Active
- 2016-07-20 DK DK20181616.2T patent/DK3733187T3/da active
- 2016-07-20 BR BR112018001065-0A patent/BR112018001065A2/pt not_active Application Discontinuation
- 2016-07-20 AU AU2016296878A patent/AU2016296878B2/en active Active
- 2016-07-20 RU RU2018106245A patent/RU2728579C2/ru active
- 2016-07-20 RU RU2020123800A patent/RU2020123800A/ru unknown
- 2016-07-20 SM SM20240496T patent/SMT202400496T1/it unknown
- 2016-07-20 CN CN201680052319.6A patent/CN108026109B/zh active Active
- 2016-07-20 MX MX2018000718A patent/MX2018000718A/es unknown
- 2016-07-20 RS RS20241314A patent/RS66238B1/sr unknown
-
2018
- 2018-01-11 IL IL256868A patent/IL256868B/en active IP Right Grant
- 2018-01-19 ZA ZA2018/00416A patent/ZA201800416B/en unknown
- 2018-10-23 HK HK18113572.9A patent/HK1254606A1/zh unknown
-
2020
- 2020-08-20 US US16/998,763 patent/US11452725B2/en active Active
-
2022
- 2022-08-15 US US17/819,858 patent/US20230346786A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3371152T3 (da) | Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
| DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3416945T3 (da) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| DK3258964T3 (da) | Detektion og behandling af maligne tumorer i CNS | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| DK3125885T3 (da) | Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer |